Skip to content
Ceftriaxone
Rocephin (ceftriaxone) is a small molecule pharmaceutical. Ceftriaxone was first approved as Rocephin on 1984-12-21. It is used to treat acinetobacter infections, bacterial infections, bacterial meningitis, bacterial pneumonia, and bacterial skin diseases amongst others in the USA.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
digestive system diseasesD004066
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
nervous system diseasesD009422
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ceftriaxone sodium
Tradename
Company
Number
Date
Products
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINERB. Braun MedicalN-050796 RX2005-04-20
2 products, RLD, RS
Show 2 discontinued
Ceftriaxone sodium
+
Lidocaine
Tradename
Company
Number
Date
Products
ROCEPHIN KITRocheN-050585 DISCN1996-05-08
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
ceftriaxoneANDA2022-01-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acinetobacter infectionsEFO_1000792D000151—
bacterial infections—D001424A49
bacterial meningitisEFO_1000831D016920G00
bacterial pneumoniaEFO_1001272D018410J15.9
bacterial skin diseases—D017192—
bacteroidaceae infectionsEFO_1000872D016866—
chancroid—D002602A57
clostridium infectionsEFO_1000874D003015A05.2
enteritis—D004751K52.9
epididymitisHP_0000031D004823N45.1
Show 18 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DD: Third-generation cephalosporins
— J01DD04: Ceftriaxone
— J01DD54: Ceftriaxone, combinations
— J01DD63: Ceftriaxone and beta-lactamase inhibitor
HCPCS
Code
Description
J0696
Injection, ceftriaxone sodium, per 250 mg
Clinical
Clinical Trials
133 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PneumoniaD011014EFO_0003106J18—183213
GonorrheaD006069DOID_7551A54—341—8
InfectionsD007239EFO_0000544—143—7
Urinary tract infectionsD014552EFO_0003103N39.0—142—7
Intraabdominal infectionsD059413——52—7
AppendicitisD001064EFO_0007149K37—1—326
Lyme neuroborreliosisD020852—11125
Septic shockD012772A48.3——1214
SepsisD018805A41.9——1124
Respiratory tract infectionsD012141J06.9——1113
Show 30 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bacterial pneumoniaD018410EFO_1001272J15.9—35——8
Lyme diseaseD008193A69.2—12——3
Hiv infectionsD015658EFO_0000764B20—11—23
Bacterial infectionsD001424A49——1—12
MalnutritionD044342EFO_0008572E40-E46—11——2
Antibiotic prophylaxisD019072—11——2
Community-acquired infectionsD017714——1——1
Microbial drug resistanceD004352——1——1
PharmacokineticsD010599—11——1
Amyotrophic lateral sclerosisD000690EFO_0000253G12.21——1——1
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—31———3
Chlamydia infectionsD002690EFO_0007205A74.9—1——12
Bipolar disorderD001714EFO_0000289F30.9—1——12
Ulcerative colitisD003093EFO_0000729K51—1———1
Inflammatory bowel diseasesD015212EFO_0003767—1———1
Parkinson diseaseD010300EFO_0002508G20—1———1
EndometritisD004716EFO_1001312—1———1
Pelvic inflammatory diseaseD000292EFO_1001388N70-N77—1———1
SchizophreniaD012559EFO_0000692F2011———1
Psychotic disordersD011618F20.8111———1
Show 9 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Erectile dysfunctionD007172EFO_0004234F52.21————11
JaundiceD007565HP_0000952R17————11
CellulitisD002481EFO_0003035L03.90————11
Aseptic meningitisD008582EFO_1000823G03.0————11
Salmonella infectionsD012480EFO_1001418A02.9————11
NeurosyphilisD009494EFO_0007339A50.4————11
Respiratory distress syndromeD012128EFO_1000637J80————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEFTRIAXONE
INNceftriaxone
Description
Ceftriaxone is a third-generation cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups. It has a role as an antibacterial drug, an EC 3.5.2.6 (beta-lactamase) inhibitor and a drug allergen. It is a cephalosporin, a member of 1,2,4-triazines, a member of 1,3-thiazoles and an oxime O-ether. It is a conjugate acid of a ceftriaxone(1-).
Classification
Small molecule
Drug classcephalosporins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1
Identifiers
PDB—
CAS-ID73384-59-5
RxCUI2193
ChEMBL IDCHEMBL161
ChEBI ID29007
PubChem CID5479530
DrugBankDB01212
UNII ID75J73V1629 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Rocephin - Roche
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 48,444 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
679 adverse events reported
View more details